Literature DB >> 32865069

Investigation of the Role of Interleukin 6 in Vitiligo Pathogenesis.

Mala Singh1, Shahnawaz D Jadeja1, Jayvadan Vaishnav1, Mohmmad Shoab Mansuri1, Chandni Shah1, Jay M Mayatra1, Atul Shah2, Rasheedunnisa Begum1.   

Abstract

Interleukin-6 (IL6) is involved in pathogenesis of several autoimmune disorders including vitiligo. Hence, we aimed to investigate the association of IL6 -174 G/C and -572 G/C polymorphisms and its transcript levels with vitiligo; to evaluate the effect of IL-6 on normal human melanocyte (NHM) viability and expression of IL6R, MITF and TYR. IL6 -174 G/C and -572 G/C polymorphisms were genotyped by ARMS-PCR and PCR-RFLP respectively in 343 controls and 322 vitiligo patients. IL6 transcript levels were estimated from PBMCs (96 controls and 77 patients) and skin samples (15 controls and 15 patients) by qPCR. NHM viability was assessed by MTT; IL6R, MITF and TYR transcript and protein levels were monitored by qPCR and ICC respectively. Genetic analyses revealed no association of IL6 -174 G/C polymorphism (p> .05) with vitiligo. Analysis of IL6 -572 G/C revealed reduced risk of vitiligo in individuals with GC/CC genotypes compared to GG genotype (p = .010). IL6 expression was significantly increased (p = .0197) in PBMCs of patients. Further, IL6 expression was significantly higher in non-lesional skin compared to controls (p = .009). In-vitro NHM viability was decreased upon IL-6 exposure (10-50 ng/ml; p< .05), with significantly increased IL6R transcript (p = .042) and protein levels (p = .003) however, MITF transcript (p = .0003) and protein levels (p = .016), and TYR transcript levels (p = .001) were significantly decreased. The results suggest that IL6 -572 G/C polymorphism might be associated with vitiligo susceptibility in Gujarat population. Moreover, increased IL6 expression in vitiligo patients and its effect on NHM suggest a potential role in melanocyte biology.
CONCLUSION: The results suggest that IL6 - 572 G/C polymorphism might be associated with vitiligo susceptibility in Gujarat population. Moreover, increased IL6 expression in vitiligo patients and its effect on NHM suggest a potential role in melanocyte biology.

Entities:  

Keywords:  Vitiligo; autoimmunity; cytokine; melanocyte; polymorphisms

Mesh:

Substances:

Year:  2020        PMID: 32865069     DOI: 10.1080/08820139.2020.1813756

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  6 in total

1.  Effects of a Traditional Caraway Formulation on Experimental Models of Vitiligo and Mechanisms of Melanogenesis.

Authors:  Abudujilili Abuduaini; Xueying Lu; Deng Zang; Tao Wu; Haji Akbar Aisa
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-19       Impact factor: 2.629

Review 2.  Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments.

Authors:  Paolo Custurone; Luca Di Bartolomeo; Natasha Irrera; Francesco Borgia; Domenica Altavilla; Alessandra Bitto; Giovanni Pallio; Francesco Squadrito; Mario Vaccaro
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

Review 3.  Current Concepts of Vitiligo Immunopathogenesis.

Authors:  Nika Hlača; Tina Žagar; Marija Kaštelan; Ines Brajac; Larisa Prpić-Massari
Journal:  Biomedicines       Date:  2022-07-08

4.  Association Among MIF, IFIH1, and IL6 Gene Polymorphisms and Non-Segmental Vitiligo in a Chinese Han Population.

Authors:  Danfeng Wang; Shuhui Min; Xiao Lin; Guan Jiang
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-10

Review 5.  A Concise Review on the Role of Endoplasmic Reticulum Stress in the Development of Autoimmunity in Vitiligo Pathogenesis.

Authors:  Shahnawaz D Jadeja; Jay M Mayatra; Jayvadan Vaishnav; Nirali Shukla; Rasheedunnisa Begum
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

6.  Elevated X-Box Binding Protein1 Splicing and Interleukin-17A Expression Are Associated With Active Generalized Vitiligo in Gujarat Population.

Authors:  Shahnawaz D Jadeja; Jayvadan Vaishnav; Ankit H Bharti; Rasheedunnisa Begum
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.